• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Transl Med . Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans

tetano

Editor, Senior Moderator
Sci Transl Med


. 2020 Dec 9;12(573):eabd3601.
doi: 10.1126/scitranslmed.abd3601.
Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans


Haley L Dugan[SUP] 1 [/SUP], Jenna J Guthmiller[SUP] 2 [/SUP], Philip Arevalo[SUP] 3 [/SUP], Min Huang[SUP] 2 [/SUP], Yao-Qing Chen[SUP] 2 [/SUP], Karlynn E Neu[SUP] 1 [/SUP], Carole Henry[SUP] 2 [/SUP], Nai-Ying Zheng[SUP] 2 [/SUP], Linda Yu-Ling Lan[SUP] 1 [/SUP], Micah E Tepora[SUP] 2 [/SUP], Olivia Stovicek[SUP] 2 [/SUP], Dalia Bitar[SUP] 2 [/SUP], Anna-Karin E Palm[SUP] 2 [/SUP], Christopher T Stamper[SUP] 1 [/SUP], Siriruk Changrob[SUP] 2 [/SUP], Henry A Utset[SUP] 2 [/SUP], Lynda Coughlan[SUP] 4 [/SUP], Florian Krammer[SUP] 4 [/SUP], Sarah Cobey[SUP] 3 [/SUP], Patrick C Wilson[SUP] 5 2 [/SUP]



Affiliations

Abstract

Humans are repeatedly exposed to variants of influenza virus throughout their lifetime. As a result, preexisting influenza-specific memory B cells can dominate the response after infection or vaccination. Memory B cells recalled by adulthood exposure are largely reactive to conserved viral epitopes present in childhood strains, posing unclear consequences on the ability of B cells to adapt to and neutralize newly emerged strains. We sought to investigate the impact of preexisting immunity on generation of protective antibody responses to conserved viral epitopes upon influenza virus infection and vaccination in humans. We accomplished this by characterizing monoclonal antibodies (mAbs) from plasmablasts, which are predominantly derived from preexisting memory B cells. We found that, whereas some influenza infection-induced mAbs bound conserved and neutralizing epitopes on the hemagglutinin (HA) stalk domain or neuraminidase, most of the mAbs elicited by infection targeted non-neutralizing epitopes on nucleoprotein and other unknown antigens. Furthermore, most infection-induced mAbs had equal or stronger affinity to childhood strains, indicating recall of memory B cells from childhood exposures. Vaccination-induced mAbs were similarly induced from past exposures and exhibited substantial breadth of viral binding, although, in contrast to infection-induced mAbs, they targeted neutralizing HA head epitopes. Last, cocktails of infection-induced mAbs displayed reduced protective ability in mice compared to vaccination-induced mAbs. These findings reveal that both preexisting immunity and exposure type shape protective antibody responses to conserved influenza virus epitopes in humans. Natural infection largely recalls cross-reactive memory B cells against non-neutralizing epitopes, whereas vaccination harnesses preexisting immunity to target protective HA epitopes.
 
Back
Top Bottom